home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

7.100 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) showing high EPS and FCF growth while beating expectations ↗

December 26, 2023

Exploring growth characteristics of ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT).

Via Chartmill

CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

December 21, 2023

From Arcturus Therapeutics

Via Business Wire

7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar ↗

December 17, 2023

While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside.

Via InvestorPlace

3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024 ↗

December 13, 2023

These biotech stocks with promising pipelines are showing some major promise and growth potential for the new year.

Via InvestorPlace

Arcturus Therapeutics: Q3 Earnings Insights ↗

November 14, 2023

Via Benzinga

Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside ↗

December 13, 2023

Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space.

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

December 04, 2023

Via Benzinga

Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 04, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Why the growth investor may take a look at NASDAQ:ARCT. ↗

December 04, 2023

ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) may be suited for growth investing, we'll explore why in this article.

Via Chartmill

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults

November 28, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis

November 27, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Target Reports Earnings Beat, Joins AST SpaceMobile, Dada Nexus And Other Big Stocks Moving Higher On Wednesday ↗

November 15, 2023

U.S. stocks traded higher, with the Dow Jones gaining more than 100 points on Wednesday. Shares of Target Corporation (NYSE: TGT) jumped during Wednesday’s session after the company reported...

Via Benzinga

Topics Earnings Stocks

Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

November 15, 2023

Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results.

Via Benzinga

Why CorMedix Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket ↗

November 15, 2023

Shares of CorMedix Inc. (NASDAQ: CRMD) surged in pre-market trading as the company posted a narrower-than-expected third-quarter loss. Cormedix posted a loss of 17 cents per share for the third...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

November 15, 2023

It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday!

Via InvestorPlace

Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress

November 14, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

The 3 Most Undervalued Biotech Stocks to Buy: November 2023 ↗

November 14, 2023

Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits.

Via InvestorPlace

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023

October 25, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

October 23, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government

October 04, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

A Look Into Healthcare Sector Value Stocks ↗

October 02, 2023

Via Benzinga

Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis

September 26, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants

September 19, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19

September 05, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Attend Upcoming Investor Conferences

August 17, 2023

From Arcturus Therapeutics

Via Business Wire

Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government

August 14, 2023

From Arcturus Therapeutics

Via Business Wire

Akamai Technologies, Array Technologies Music, HNI, PENN Entertainment And Other Big Stocks Moving Higher On Wednesday ↗

August 09, 2023

U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Why Shares of Arcturus Therapeutics Dropped on Tuesday ↗

August 08, 2023

The company saw revenue decline and net losses rise in the second quarter.

Via The Motley Fool

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 08, 2023

Via Benzinga

Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

August 08, 2023

Gainers Nuburu, Inc. (NYSE: BURU) shares jumped 185.6% to $1.6593 after the company announced contract with NASA to demonstrate feasibility of power beaming in space using the company’s blue laser...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com